Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04324606
Other study ID # COV001
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 23, 2020
Est. completion date March 31, 2024

Study information

Verified date July 2023
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years. The vaccine will be administered intramuscularly (IM) into the deltoid region of the arm


Description:

There will be 4 study groups and it is anticipated that a total of 1090 volunteers will be enrolled. Volunteers will participate in the study for approximately 12 months from last vaccination visit (approximately 15 months from enrolment for participants receiving 2 doses)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1090
Est. completion date March 31, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria The volunteer must satisfy all the following criteria to be eligible for the study: - Healthy adults aged 18-55 years. - Able and willing (in the Investigator's opinion) to comply with all study requirements (participants must not rely on public transport or taxis). - Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner and access all medical records when relevant to study procedures. - For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination. - Agreement to refrain from blood donation during the course of the study. - Provide written informed consent. Exclusion Criteria The volunteer may not enter the study if any of the following apply: - Planned receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination .with the exception of the licensed seasonal influenza vaccination and the licensed pneumococcal vaccine. Participants will be encouraged to receive this vaccination at least 7 days before or after their study vaccine. - Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines). - Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. - Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting <14 days) . - Any autoimmune conditions, except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease not requiring immunosuppressive or immunomodulatory therapy. - History of allergic disease or reactions likely to be exacerbated by any component of the ChAdOx1 nCoV-19 or MenACWY vaccines. - Any history of angioedema . - Any history of anaphylaxis . - Pregnancy, lactation or willingness/intention to become pregnant during the study. - History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). - History of serious psychiatric condition likely to affect participation in the study (e.g. ongoing severe depression, history of admission to an in-patient psychiatric facility, recent suicidal ideation, history of suicide attempt, bipolar disorder, personality disorder, alcohol and drug dependency, severe eating disorder, psychosis, use of mood stabilisers or antipsychotic medication). - Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. - Any other serious chronic illness requiring hospital specialist supervision. - Chronic respiratory diseases, including mild asthma (resolved childhood asthma is allowed) - Chronic cardiovascular disease (including hypertension), gastrointestinal disease, liver disease (except Gilberts Syndrome), renal disease, endocrine disorder (including diabetes) and neurological illness (excluding migraine) - Seriously overweight (BMI=40 Kg/m2) or underweight (BMI=18 Kg/m2) - Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week. - Suspected or known injecting drug abuse in the 5 years preceding enrolment. - Any clinically significant abnormal finding on screening biochemistry, haematology blood tests or urinalysis. - Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. - History of laboratory confirmed COVID-19. - New onset of fever or a cough or shortness of breath or anosmia/ageusia since February 2020. Should a reliable test become available, this exclusion criteria will be replaced with seropositivity for SARS-CoV-2 before enrolment. - Those who have been at high risk of exposure before enrolment, including but not limited to: close contacts of confirmed COVID-19 cases, anyone who had to self-isolate as a result of a symptomatic household member, frontline healthcare professionals working in A&E, ICU and other higher risk areas. Should a reliable test become available, this exclusion criteria will be replaced with seropositivity for SARS-CoV-2 before enrolment. - Living in the same household as any vulnerable groups at risk of severe COVID-19 disease (as per Public Health England guidance) Additional exclusion criteria (subset of participants receiving Paracetamol in group 4 only) • History of allergic disease or reactions likely to be exacerbated by Paracetamol Re-vaccination exclusion criteria: The following AEs associated with any vaccine, or identified on or before the day of vaccination constitute absolute contraindications to further administration of an IMP to the volunteer in question. If any of these events occur during the study, the subject will not be eligible to receive a booster dose and will be followed up by the clinical team or their GP until resolution or stabilisation of the event: - Anaphylactic reaction following administration of vaccine - Pregnancy. An exception to this will be prior to receipt of a booster dose at extra visit B. If a pregnant woman has discussed vaccination with their usual clinician (e.g. GP) and chooses to receive a COVID-19 vaccination, this may be administered by the trial team as part of extra visit B or as part of the provision of treatment to controls - Any AE that in the opinion of the Investigator may affect the safety of the participant or the interpretation of the study results

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ChAdOx1 nCoV-19
A single dose of 5x10^10vp of ChAdOx1 nCoV-19
MenACWY
Standard single dose of MenACWY vaccine delivered intramuscularly
ChAdOx1 nCoV-19 full boost
A single dose of 5x10^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10^10vp of ChAdOx1 nCoV-19
ChAdOx1 nCoV-19 half boost
A single dose of 5x10^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10^10vp of ChAdOx1 nCoV-19
MenACWY boost
A standard dose of MenACWY followed by a boost dose of MenACWY
Drug:
Paracetamol
1g every 6 hours for 24 hours
Biological:
ChAdOx1 nCoV-19 0.5mL boost
A single dose of 5x10^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp)
ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)
A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) 9 months after receiving a single or double dose of 5x10^10vp of ChAdOx1 nCoV-19
ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)
A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later

Locations

Country Name City State
United Kingdom University Hospitals Bristol and Weston NHS Foundation Trust Bristol
United Kingdom Imperial College Healthcare NHS Trust London
United Kingdom St Georges University Hospital NHS Foundation Trust London
United Kingdom CCVTM, University of Oxford, Churchill Hospital Oxford
United Kingdom John Radcliffe Hospital Oxford
United Kingdom University Hospital Southampton NHS Foundation Trust Southampton Hampshire

Sponsors (1)

Lead Sponsor Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through Virus neutralising antibody assays Virus neutralising antibody (NAb) assays against live and/or pseudotype SARS-CoV-2 virus 6 months
Other Assess safety, reactogenicity, immunogenicity and efficacy endpoints, for participants receiving prophylactic paracetamol All safety, reactogenicity, immunogenicity and efficacy endpoints 6 months
Other Assess immunogenicity of ChAdOx1 nCoV-19 given as homologous prime-boost Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates) post boost 6 months
Other Compare viral shedding on stool samples of SARS-CoV-2 PCR or NAAT positive individuals Differences in viral shedding on stool between vaccine and comparator arms at 7 days and beyond post SARS-CoV-2 PCR or NAAT positivity 6 months
Other Assess immunogenicity of a delayed three dose ChAdOx1 nCoV-19 schedule Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates) post boost Blood samples drawn at LV14, LV28 and LV182
Other assess immunological correlates of protection in relation to occurrence of COVID-19 disease in ChAdOx1 nCoV-19 recipients Immunological endpoints (antibody & cellular responses to SARS-COV2 spike protein) and COVID-19 disease endpoints (SARS-COV2 PCR positivity plus symptoms) in ChAdOx1 nCoV-19 recipients Throughout the study, average of 18 months
Primary Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases Number of virologically confirmed (PCR or NAAT positive) symptomatic cases of COVID-19 6 months
Primary Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs) Occurrence of serious adverse events (SAEs) throughout the study until a cutoff date of 1st July 2021 or 6 months post late vaccination visit, whichever is latest Throughout the study, average of 18 months
Secondary Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination 7 days following vaccination
Secondary Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following vaccination 7 days following vaccination
Secondary Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs) Occurrence of unsolicited adverse events (AEs) for 28 days following vaccination (7 days following vaccination for groups 1c, 1d, 5a & 5b) 7 or 28 days following vaccination
Secondary Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests Change from baseline for safety laboratory measures (haematology and biochemistry blood results) 6 months
Secondary Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes Occurrence of disease enhancement episodes 6 months
Secondary Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by hospital admissions Number of hospital admissions associated with COVID-19 6 months
Secondary Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by ICU admissions Number of intensive care unit admissions associated with COVID-19 6 months
Secondary Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by COVID-19 related deaths Number of deaths associated with COVID-19 6 months
Secondary Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 Occurrence of severe COVID-19 disease (defined according to clinical severity scales) 6 months
Secondary Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates Proportion of people who become seropositive for non-Spike SARS-CoV-2 antigens during the study 6 months
Secondary Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays Interferon-gamma (IFN-?) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein 6 months
Secondary Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates) 6 months
See also
  Status Clinical Trial Phase
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT05359770 - Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19 N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Not yet recruiting NCT06025812 - Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) N/A
Recruiting NCT05289115 - Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS N/A
Completed NCT04953078 - A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 Phase 1
Completed NCT04779138 - Increasing Vaccine Uptake in Underresourced Public Housing Areas N/A
Not yet recruiting NCT05868239 - Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study N/A
Completed NCT04818164 - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04572399 - UVA Light Device to Treat COVID-19 N/A
Recruiting NCT04610567 - Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) Phase 1/Phase 2
Recruiting NCT04772170 - Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Recruiting NCT04581954 - Inflammatory Signal Inhibitors for COVID-19 (MATIS) Phase 1/Phase 2
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Completed NCT05572840 - Wear Your Mask, Wash Your Hands, Don't Get COVID-19 N/A
Withdrawn NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 Phase 3
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3